Contact US

You have any questions or need to contact us about something? Reach out, we’d be happy to hear from you!

ask.pathinvestments@gmail.com

  • twitter
  • facebook
  • linkedin

All the Latest

Welcome to Path Investments

Please reload

Archive

Please reload

Tags

Our Recent Posts

Please reload

February 9, 2017

Gilead's pipeline has a newly approved drug for treating HBV (Vemlidy) and phase 3 trials in NASH. Both these diseases represent huge opportunities for Gilead since there there are a vast number of patients and no reasonable treatment options in either. In 2017 I expect Gilead to proceed with M&A as well as activist investment into the company....

Please reload

 
 
 

©2017 by Path Investments.

  • twitter
  • facebook
  • linkedin